Drugs that are only available currently for the emergency treatment of acute severe pain are opioids, ketamine, and methoxyflurane and nitrous oxide. All these drugs have substantial side effects that severely limit their use. In particular, the deployment of ketamine is limited by a high incidence of severe dysphoric psychotic states, that occur around the same dosage as is required for analgesia.
It has been discovered that some analogues of ketamine seem to show good analgesia without these hallucinatory side effects. This suggests that they might be acting on different molecular analgesic targets than those typically ascribed to ketamine. In particular potassium channels seem to be likely targets, because we have shown that injection of a potassium channel blocker antagonises the analgesia of one of the ketamine analogues – R5. This would strongly suggest that positive modulation of one or more potassium channels, plays a pivotal role in mediating the ketamine-analogue analgesia. The research team used computer simulations of various ketamine-like drugs, and their binding to potassium channels, to understand which potassium channels are important mediators of the analgesic action – and the molecular mechanisms that underly how the analogues alter the channel protein structure.
Professor Jamie Sleigh, Waikato Hospital, New Zealand
The project was awarded $A55,000 through the ANZCA research grants program for 2022.
This work provided a comprehensive description of the molecular binding and resultant analgesia as regards the TWIK1 channel. It has shown that the computer molecular dynamic simulations of drug binding to potassium channels, embedded in a lipid bilayer membrane, show plausible and reproducible results within the 1 µsec simulation times. When testing various compounds, there is a good correlation between analgesic potency and increased potassium current flow. It was also discovered that the details of the molecular binding sites, and the allosteric alterations in the shape of the selectivity filter mediates the increased potassium current.
The research has three implications and outcomes:
- Established the TWIK1 channel as a plausible mediator of analgesia. For various technical experimental reasons, the TWIK1 channel has not been intensively investigated previously. The combination of ex vivo experiments and our computer simulations show that TWIK1 has a role in various novel analgesic pathways.
- Provides a basic science background to support the further development of TWIK1 agonists as novel non-opioid analgesic drugs – and hopefully their introduction into clinical practice.
- Validated computer methodology to explore many other drug-receptor/channel interactions.
A manuscript is being prepared for submission to Scientific Reports or PNAS, titled “Analgesic Effects of Ketamine Analogues Mediated by the TWIK1 Channel.”
Last modified: